Eli Lilly Posts Strong Growth in Q4 with a 19% Increase in EPS

As the fiscal year draws to a close, pharmaceutical giant Eli Lilly presents its Q4 earnings report, showcasing a significant uptick in financial performance. The company's adjusted EPS (Earnings Per Share), following non-GAAP (Generally Accepted Accounting Principles) measures, saw a notable 19% rise from the previous year, reaching $2.49. This increment mirrors the company's robust sales figures, which also climbed by an impressive 28%, resulting in $9.35 billion in revenues.

Substantial Growth from New Products

One of the primary growth engines for Eli Lilly has been its array of new pharmaceutical products. Statistically, these fresh market entrants surged the revenue pool by $2.19 billion, culminating in a total of $2.49 billion. Newly introduced drugs like Mounjaro and Zepbound have been central to this financial stride. Yet, the success didn't end there as the company's existing 'growth products' also showcased a 9% revenue increase, summing up to $5.27 billion, with Verzenio and Jardiance contributing considerably to this success.

Looking Forward to 2024

Projections for the upcoming year are optimistic, as Eli Lilly anticipates its adjusted EPS to land within a range of $12.20 to $12.70. Revenue forecasts are similarly hopeful, extending between $40.4 billion to $41.6 billion. These figures neatly surpass the $6.32 EPS and $34.1 billion revenue marks recorded for the previous year, indicating strong growth expectations for the company's near future.

Pharmaceutical, EliLilly, Earnings